Access to abortion pills has grown since Dobbs

How activists, clinicians, and businesses are getting abortion medication to all 50 states.

By Rachel M. Cohen
Dec 27, 2023

Eighteen months after the Dobbs v. Jackson decision that overturned the constitutional right to abortion, and with a new Supreme Court challenge pending against the abortion medication mifepristone, confusion abounds about access to reproductive health care in America.

Since the June 2022 decision, abortion rates in states with restrictions have plummeted, and researchers estimated last month that the Dobbs decision led to “approximately 32,000 additional annual births resulting from bans.” Journalists profiled women who carried to term since Dobbs because they couldn’t afford to travel out of their restrictive state.

Continued: https://www.vox.com/policy/2023/12/27/24015092/abortion-pills-mifepristone-roe-reproductive-misoprostol

27.12.2023

Commentary

Abortion Coalition for Telemedicine

abortion pills

abortion support networks

Dobbs v. Jackson Women's Health Organization

Elisa Wells

Expanding Medication Abortion Access

Massachusetts Medication Abortion Access Project

medication abortion

mifepristone

misoprostol

misoprostol only abortions

National Abortion Federation

Plan C

Red State Access

Reproductive Health Initiative for Telehealth Equity and Solutions

self-managed abortion

shield laws

Society of Family Planning

telehealth abortion

telemedicine abortion

Fear and confusion over abortion access persists as SCOTUS takes its first post-Dobbs case

Mifepristone will likely remain legal but could prove much harder to access. Legal and pharmaceutical experts have said this case could have far-reaching implications on approval for medications beyond abortion drugs.

by KELCIE MOSELEY-MORRIS AND SOFIA RESNICK
DECEMBER 19, 2023

This year will end on a major cliffhanger for abortion access.

Last November, anti-abortion activists via a powerful conservative Christian law firm asked a federal court to effectively ban or widely restrict the abortion drug mifepristone. Finally on Wednesday, the U.S. Supreme Court agreed to take the case, making Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration the high court’s first abortion-related case since overturning the federal right to an abortion in June 2022.

Continued: https://www.thelundreport.org/content/fear-and-confusion-over-abortion-access-persists-scotus-takes-its-first-post-dobbs-case

The Biden Administration’s Investment in Internet Will Reduce Barriers to Abortion

Today, a wide range of reproductive healthcare services are available through telehealth—but only if a person has reliable internet access.

10/11/2023
by VAL DIEZ CANSECO

Millions of Americans lack access to reliable high-speed internet. But a move this summer from the Biden-Harris administration—a $42.45 billion investment in affordable high-speed internet—will no doubt help to close this digital divide. Promoting equity in internet access is especially urgent in a post-Roe world, where 21 states have moved to ban or restrict abortion, all while telehealth abortion capabilities are increasing.

The Broadband Equity Access and Deployment (BEAD) grant program, announced in June, is a commitment to connect all Americans to affordable high-speed internet by 2030. Created under the Bipartisan Infrastructure Law, BEAD requires states to prioritize unserved areas before improving service elsewhere.

Continued: https://msmagazine.com/2023/10/11/biden-internet-broadband-abortion-pills-telehealth/

11.10.2023

News

Broadband Equity Access and Deployment

Broadband Now

Dana Northcraft

Internet access and abortion

Nancy Skinner

Reproductive Health Initiative for Telehealth Equity and Solutions

United States

Politics

A Trump-Stacked Court Hopes to Limit Access to the Abortion Pill. The Final Decision Now Lies With SCOTUS.

8/17/2023
by CARRIE N. BAKER, Ms. Magazine

The Fifth Circuit Court of Appeals released a decision on Wednesday, Aug. 16, that dismissed a challenge to the U.S. Food and Drug Administration’s 2000 approval of mifepristone, but would sharply restrict access to medication abortion nationwide and eliminate telemedicine abortion. The decision in Alliance for Hippocratic Medicine v. FDA remains on hold until final review by the U.S. Supreme Court.

“While the court has acknowledged that mifepristone—both brand and generic versions—can stay on the market, they are insisting we should roll back the clock to 2000 and put the medication under lock and key,” said Kirsten Moore, director of Expanding Medication Abortion Access Project (EMAA Project). “The extremist judges ignored the FDA, our basic rights, and more than 20 years of scientific evidence showing mifepristone is safe and effective, rolling back decades of advancement in the standard of care. This is a dangerous precedent for FDA’s scientific review authority.”

Continued: https://msmagazine.com/2023/08/17/abortion-pills-fifth-circuit-mifepristone/